SAN DIEGO, Sept. 21 /PRNewswire/ -- ChemBridge Corporation and ChemBridge Research Laboratories, Inc. (CRL) today announced a multi-year collaboration in discovery chemistry with AstraZeneca. In accordance with the agreement ChemBridge and CRL scientists at Moscow and San Diego research sites will work closely with AstraZeneca scientists to develop highly advanced exclusive small molecule libraries enhancing AstraZeneca's global drug discovery effort. Further details and financial terms were not disclosed.
"We are very pleased that after worldwide evaluation and due diligence AstraZeneca has selected ChemBridge and CRL as one of their chemistry partners," said Eugene Vaisberg, Chairman and CEO of ChemBridge Corporation and CRL. "This new agreement serves as yet another confirmation of the excellent capabilities of CRL and ChemBridge in the expertise-driven area of small molecule research. We look forward to contributing our proven chemistry expertise to AstraZeneca's global drug discovery program."
Dr. Paul Leff, VP of Discovery Enabling Capabilities and Sciences, AstraZeneca adds, "We chose to work with ChemBridge and CRL because of their reputation and abilities in drug discovery chemistry and library synthesis. I am confident that we will see promising outcomes resulting from this collaboration in the area of lead generation."
About ChemBridge Corporation
ChemBridge Corporation, www.chembridge.com, is a leading global discovery chemistry CRO with an impeccable track record of quality and deliverability. ChemBridge was founded in Chicago in 1993 and has grown to a global company with 350 employees. ChemBridge has its corporate headquarters in San Diego, European office in the UK, and a marketing agency in Japan. It also operates a large, state-of-the-art offshore discovery chemistry research site in Moscow, Russia. Over 400 pharmaceutical and biotech companies and universities worldwide have taken advantage of ChemBridge's portfolio of advanced discovery chemistry services and products, including its library of 700,000 diverse drug-like small molecule compounds.
About ChemBridge Research Laboratories, Inc.
ChemBridge Research Laboratories, Inc. (CRL), www.chembridgeresearch.com, a biotech company based in San Diego, provides chemistry solutions for all stages of the drug discovery process. Founded in 2000 as a spin-off of ChemBridge Corporation, CRL has built a world-class research organization and a track record of exceeding expectations in all its collaborations, including multi-year strategic alliances with Pfizer and Merck. CRL provides a competitive edge to its partners through its comprehensive medicinal chemistry platform, which encompasses efficient high-throughput and large scale chemistry supported by analytical and computational chemistry and bioassay capabilities. With a core expertise in key drug target families and access to ChemBridge's entire chemistry tools portfolio, CRL excels at the design and synthesis of custom screening and hit to lead libraries as well as lead optimization and collaborative discovery chemistry projects.
CRL's list of recent partnerships include contract research collaborations with leading pharmaceutical and biotech companies such as Eisai, Genomics Institute of the Novartis Research Foundation, GlaxoSmithKline, Memorial Sloan-Kettering Cancer Center, Merck KGaA, Tanabe and Tularik.
About AstraZeneca
AstraZeneca is a major international healthcare business engaged in research, development, manufacturing and marketing of prescription pharmaceuticals and supplier for healthcare services. AstraZeneca is one of the world's leading pharmaceutical companies with healthcare sales of US $23.95 billion and is a leader in gastrointestinal, cardiovascular, neuroscience, respiratory, oncology and infection product sales. AstraZeneca is listed in the Dow Jones Sustainability Index (Global) as well as the FTSE4Good Index. For more information please visit: www.astrazeneca.com.
ChemBridge CorporationCONTACT: Eugene Vaisberg, Chairman & CEO of ChemBridge Corporation andCRL, +1-858-451-7400, ext. 110
